Related references
Note: Only part of the references are listed.Effect of Allopurinol in Chronic Kidney Disease Progression and Cardiovascular Risk
Marian Goicoechea et al.
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2010)
Acute Renal Failure and Its Risk Factors in Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis
Chi-Chih Hung et al.
AMERICAN JOURNAL OF NEPHROLOGY (2009)
A critical reappraisal of allopurinol dosing, safety, and efficacy for hyperuricemia in gout
Jeannie Chao et al.
Current Rheumatology Reports (2009)
The Janus Faces of Allopurinol—Allopurinol Hypersensitivity Syndrome
Anne-Kathrin Tausche et al.
AMERICAN JOURNAL OF MEDICINE (2008)
Allopurinol is the most common cause of Stevens-Johnson syndrome and toxic epidermal necrolysis in Europe and Israel
Sitna Halevy et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2008)
Uric acid and incident kidney disease in the community
Daniel E. Weiner et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2008)
Elevated Uric Acid Increases the Risk for Kidney Disease
Rudolf P. Obermayr et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2008)
A European study of HLA-B in Stevens-Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs
Christine Lonjou et al.
PHARMACOGENETICS AND GENOMICS (2008)
HLA-B locus in Japanese patients with anti-epileptics and allopurinol-related Stevens-Johnson syndrome and toxic epidermal necrolysis
Nahoko Kaniwa et al.
PHARMACOGENOMICS (2008)
Pleiotropic effects of statin therapy: molecular mechanisms and clinical results
Chao-Yung Wang et al.
TRENDS IN MOLECULAR MEDICINE (2008)
Preemptive HMG-CoA reductase inhibition provides graft-versus-host disease protection by Th-2 polarization while sparing graft-versus-leukemia activity
Robert Zeiser et al.
BLOOD (2007)
Expressing the modification of diet in renal disease study equation for estimating glomerular filtration rate with standardized serum creatinine values
Andrew S. Levey et al.
CLINICAL CHEMISTRY (2007)
The effect of mild hyperuricemia on urinary transforming growth factor beta and the progression of chronic kidney disease
Khaled M. Talaat et al.
AMERICAN JOURNAL OF NEPHROLOGY (2007)
Cutting edge: Elimination of an endogenous adjuvant reduces the activation of CD8 T lymphocytes to transplanted cells and in an autoimmune diabetes model
Yan Shi et al.
JOURNAL OF IMMUNOLOGY (2006)
Therapeutic effects of xanthine oxidase inhibitors: Renaissance half a century after the discovery of allopurinol
P Pacher et al.
PHARMACOLOGICAL REVIEWS (2006)
Lesson of the week -: Fatal allopurinol hypersensitivity syndrome after treatment of asymptomatic hyperuricaemia
A Gutiérrez-Macías et al.
BMJ-BRITISH MEDICAL JOURNAL (2005)
HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol
SL Hung et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Molecular identification of a danger signal that alerts the immune system to dying cells
Y Shi et al.
NATURE (2003)
MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomised placebo-controlled trial
R Collins et al.
LANCET (2002)
Relation between adverse events associated with allopurinol and renal function in patients with gout
J Vázquez-Mellado et al.
ANNALS OF THE RHEUMATIC DISEASES (2001)
Innate immune recognition: mechanisms and pathways
R Medzhitov et al.
IMMUNOLOGICAL REVIEWS (2000)
Share Paper
